Issuu on Google+

Osteoporosis-Pipeline Review, H2 2016

1


Description: Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications. Request a sample of this report @ http://www.orbisresearch.com/contacts/requestsample/146170 .

Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 4, 8, 14, 1, 54 and 10 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively for Osteoporosis. Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Browse the complete report @ http://www.orbisresearch.com/reports/index/osteoporosispipeline-review-h2-2016 .

Companies Mentioned: Amgen Inc. BiologicsMD, Inc. Clonz Biotech Private Limited 2


Eli Lilly and Company Enteris BioPharma, Inc. Ligand Pharmaceuticals, Inc. Merck & Co., Inc. Oncobiologics, Inc. Paras Biopharmaceuticals Finland Oy Radius Health, Inc. If you have any enquiry before buying a copy of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/146170 .

List of Figures Number of Products under Development for Post Menopausal Osteoporosis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Targets, H1 2016 25 Number of Products by Stage and Targets, H1 2016 25 Contact sales@orbisresearch.com for more information. About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Us: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +912064101019 Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research Follow us on Twitter: https://twitter.com/orbisresearch Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115

3


Osteoporosis Market Therapeutic Pipeline H2 2016, Major Key Analysis